BACKGROUND The literature continues to report low rates of accrual to cancer clinical trials.
Previous studies have examined principally physician‐related or patient‐related barriers …

PURPOSE: Well-conducted cancer clinical trials are essential for improving patient
outcomes. Unfortunately, only 3% of new cancer patients participate in clinical trials. Barriers …

Data indicate that substantial pool of candidates exists, especially in the community setting,
for enrollment in clinical oncologic trials. However, only a small proportion of cancer patients …

Background Clinical trials are vital for evidence-based cancer care. Oncologist engagement
in clinical trials has an effect on patient recruitment, which in turn can affect trial success …

Purpose: Oncology clinical trials (OCTs) are crucial in evaluating new cancer treatments, but
only 2% to 3% of US adult patients with cancer enter OCTs. This study assessed barriers to …

Background Barriers to clinical trial enrollment have been the subject of extensive research;
however, the rate of clinical trial participation has not improved significantly over time …

It is thought by some that there are inadequate patient entries on high priority national
cancer treatment protocols, resulting in intolerable delays in addressing crucial research …

Low accrual rates may affect the completion of clinical trials essential to the development of
new cancer therapies. Patient and physician attitudes and awareness of clinical trials …

Purpose: The National Cancer Institute estimates that less than 5% of adult patients with
cancer participate in clinical trials. This statistic has to improve in order for clinical trials to be …

PURPOSE Clinical trials are essential to improve cancer therapy, but only 3% of newly
diagnosed adult cancer patients enroll annually. We previously conducted a prospective …